What question did this study set out to answer?

The objective is to compare the effectiveness of axicabtagene ciloleucel against standard regimens in treating early relapsed/refractory large B cell lymphoma.

December 8, 2025Blood

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

View Full Paper

Ask AI

Bookmark

Authors

CRCédric RossiInserm FJFabrice JardinInserm GDGandhi DamajCentre National de la Recherche Scientifique

Discussion

Member takes

Implication

Retrospective study reveals improved event-free survival with axicabtagene ciloleucel in large B cell lymphoma, suggesting advantages over traditional therapies.

Key Points

The objective is to compare the effectiveness of axicabtagene ciloleucel against standard regimens in treating early relapsed/refractory large B cell lymphoma.
Conducted a retrospective multicenter study
Analyzed patients from REALYSA and DESCAR-T registries
Used propensity scores and inverse probability weighting to balance baseline characteristics
Assessed time-to-event outcomes with Kaplan–Meier estimator
EFS at 1 year was significantly better for axi-cel at 46% compared to 16% for SOC
OS at 1 year was 64% for axi-cel versus 57% for SOC, not statistically significant
In the SOC arm, 62.4% received third-line therapy, often CAR T-cells

Cite This Study

Rossi et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db88 https://doi.org/10.1182/blood-2025-2764

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reveals improved event-free survival with axicabtagene ciloleucel in large B cell lymphoma, suggesting advantages over traditional therapies.

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider